TScan Therapeutics, Inc. – NASDAQ:TCRX
TScan Therapeutics stock price today
$1.679
-1.38
-45.13%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market open
Closed in about 5 hours
TScan Therapeutics stock price monthly change
-54.60%
month
TScan Therapeutics stock price quarterly change
-54.60%
quarter
TScan Therapeutics stock price yearly change
-49.25%
year
TScan Therapeutics key metrics
Market Cap | 157.71M |
Enterprise value | N/A |
P/E | -0.71 |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | 6.86 |
Price/Book | 0.48 |
PEG ratio | -0.02 |
EPS | -1.28 |
Revenue | 14.81M |
EBITDA | -97.97M |
Income | -96.79M |
Revenue Q/Q | -91.68% |
Revenue Y/Y | 4.14% |
Profit margin | -935.72% |
Oper. margin | -941.59% |
Gross margin | 57.31% |
EBIT margin | -941.59% |
EBITDA margin | -661.48% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeTScan Therapeutics stock price history
TScan Therapeutics stock forecast
TScan Therapeutics financial statements
| Jun 2023 | 3.14M | -24.04M | -763.82% |
|---|---|---|---|
| Sep 2023 | 3.88M | -22.99M | -591.64% |
| Dec 2023 | 7.21M | -19.61M | -271.99% |
| Mar 2024 | 566K | -30.14M | -5325.44% |
| Mar 2024 | 566K | -30.14M | -5325.44% |
|---|---|---|---|
| Sep 2025 | 2.5M | -22.76M | -910.42% |
| Oct 2025 | 1.16M | -32.25M | -2764.95% |
| Dec 2025 | 1.16M | -33.20M | -2846.28% |
Analysts Price target
Financials & Ratios estimates
| 2023-11-09 | -0.43 | -0.24 |
|---|---|---|
| 2024-03-06 | -0.3 | -0.21 |
| 2024-05-13 | -0.25 | -0.32 |
| Jun 2023 | 316923000 | 126.31M | 39.86% |
|---|---|---|---|
| Sep 2023 | 291379000 | 122.41M | 42.01% |
| Dec 2023 | 272149000 | 121.28M | 44.56% |
| Mar 2024 | 240832000 | 117.86M | 48.94% |
| Jun 2023 | -22.02M | -420K | 135.67M |
|---|---|---|---|
| Sep 2023 | 8.01M | -61.41M | -252K |
| Dec 2023 | -23.76M | 1.91M | 19K |
| Mar 2024 | -29.26M | 36.16M | 258K |
TScan Therapeutics alternative data
| Aug 2023 | 136 |
|---|---|
| Sep 2023 | 135 |
| Oct 2023 | 135 |
| Nov 2023 | 135 |
| Dec 2023 | 145 |
| Jan 2024 | 145 |
| Feb 2024 | 145 |
| Mar 2024 | 154 |
| Apr 2024 | 154 |
| May 2024 | 154 |
| Jun 2024 | 161 |
| Jul 2024 | 161 |
TScan Therapeutics other data
14.50%
-25.04%
of TCRX is owned by hedge funds
14
-14
3.48M
-6.03M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Apr 2024 | 14677419 | 0 |
| Aug 2024 | 10000 | 164686 |
| Sep 2024 | 5000 | 0 |
| Nov 2024 | 947 | 0 |
| Dec 2024 | 131800 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | LYNX1 CAPITAL MANAGEMENT LP 10 percent owner | Common Stock | 100,000 | $2.9 | $290,100 | ||
Purchase | LYNX1 CAPITAL MANAGEMENT LP 10 percent owner | Common stock, $0.0001 par value per share ("Common Stock") | 31,800 | $3.01 | $95,623 | ||
Purchase | LYNX1 CAPITAL MANAGEMENT LP 10 percent owner | Common stock, $0.0001 par value per share | 947 | $4.34 | $4,114 | ||
Purchase | KLENCKE BARBARA director | Voting Common Stock | 5,000 | $5.29 | $26,450 | ||
Purchase | KLENCKE BARBARA director | Voting Common Stock | 5,000 | $5.53 | $27,650 | ||
Purchase | KLENCKE BARBARA director | Voting Common Stock | 5,000 | $5.69 | $28,450 | ||
Option | ZDRAVESKI ZORAN officer: See Remarks | Stock Option (Right to Buy) | 64,166 | $2.49 | $159,773 | ||
Option | ZDRAVESKI ZORAN officer: See Remarks | Voting Common Stock | 64,166 | $2.49 | $159,773 | ||
Option | ZDRAVESKI ZORAN officer: See Remarks | Voting Common Stock | 13,125 | $1.81 | $23,756 | ||
Option | ZDRAVESKI ZORAN officer: See Remarks | Voting Common Stock | 25,000 | $3.27 | $81,750 |
| Insider | Compensation |
|---|---|
| Mr. David P. Southwell (1961) Pres, Chief Executive Officer & Director | $750,240 |
| Dr. Gavin MacBeath (1970) Chief Scientific Officer | $532,970 |
-
What's the price of TScan Therapeutics stock today?
One share of TScan Therapeutics stock can currently be purchased for approximately $1.68.
-
When is TScan Therapeutics's next earnings date?
Unfortunately, TScan Therapeutics's (TCRX) next earnings date is currently unknown.
-
Does TScan Therapeutics pay dividends?
No, TScan Therapeutics does not pay dividends.
-
How much money does TScan Therapeutics make?
TScan Therapeutics has a market capitalization of 157.71M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 55.52% to 21.05M US dollars. TScan Therapeutics made a loss 89.22M US dollars in net income (profit) last year or -$0.32 on an earnings per share basis.
-
What is TScan Therapeutics's stock symbol?
TScan Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "TCRX".
-
What is TScan Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of TScan Therapeutics?
Shares of TScan Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are TScan Therapeutics's key executives?
TScan Therapeutics's management team includes the following people:
- Mr. David P. Southwell Pres, Chief Executive Officer & Director(age: 64, pay: $750,240)
- Dr. Gavin MacBeath Chief Scientific Officer(age: 55, pay: $532,970)
-
How many employees does TScan Therapeutics have?
As Jul 2024, TScan Therapeutics employs 161 workers, which is 5% more then previous quarter.
-
When TScan Therapeutics went public?
TScan Therapeutics, Inc. is publicly traded company for more then 4 years since IPO on 16 Jul 2021.
-
What is TScan Therapeutics's official website?
The official website for TScan Therapeutics is tscan.com.
-
Where are TScan Therapeutics's headquarters?
TScan Therapeutics is headquartered at 830 Winter Street, Waltham, MA.
-
How can i contact TScan Therapeutics?
TScan Therapeutics's mailing address is 830 Winter Street, Waltham, MA and company can be reached via phone at 857 399 9500.
TScan Therapeutics company profile:
TScan Therapeutics, Inc.
tscan.comExchange:
NASDAQ
Full time employees:
188
Industry:
Biotechnology
Sector:
Healthcare
TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. The company is also developing vaccines for infectious diseases, such as SARS-CoV-2. It has a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc., to identify novel cancer antigens from the T cells of patients with a certain specific type of cancer. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
830 Winter Street
Waltham, MA 02451
Waltham, MA 02451
CIK: 0001783328
ISIN: US89854M1018
CUSIP: 89854M101
